Physician profile
Amanda D Smith
NPI 1508467010
$2,774.53
in general payments reported to CMS, 2019-2025
27 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.14 · 2022: $187 · 2023: $965 · 2024: $487 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077 · Education: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.43 |
| Education | $426.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $630.04 | 2022-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $376.96 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $349.89 | 2023-2025 | |
| Ucb, INC. | $204.79 | 2024-2025 | Bimzelx |
| Amgen INC. | $165.69 | 2021-2025 | Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.93 | 2025 | Xifaxan |
| Lilly USA, LLC | $119.62 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $110.77 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $100.22 | 2023-2024 | Winlevi, Absorica Ld, Blu-U |
| Astrazeneca Pharmaceuticals LP | $84.11 | 2021-2022 | |
| Incyte Corporation | $81.84 | 2023-2025 | Opzelura |
| Novo Nordisk INC | $54.53 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.13 | 2023 | Sotyktu |
| Glaxosmithkline, LLC. | $34.27 | 2024-2025 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $31.10 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $30.85 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.59 | 2023 | Spevigo |
| Biohaven Pharmaceutical Holding Company LTD. | $24.46 | 2022 | |
| Hologic Sales and Service, LLC | $24.27 | 2022 | |
| Galderma Laboratories, L.P. | $23.77 | 2025 | Nemluvio |
| Organon LLC | $21.60 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $20.07 | 2024 | Nuzyra |
| Kyowa Kirin, INC. | $18.64 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.79 | 2025 | |
| Leo Pharma INC. | $16.37 | 2024 | Adbry |
| Pfizer INC. | $15.27 | 2023 | |
| Mayne Pharma Commercial LLC | $14.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.